Summary of TACTIC-E protocol published by BMC
A structured summary of a study protocol for a randomised controlled trial of Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E) has been published in the BioMed Central Journal.
The TACTIC-E clinical trial is testing whether novel therapeutic agents or novel combinations of approved agents can prevent the development of severe symptoms in patients hospitalised with strongly suspected or confirmed COVID-19. By targeting the exaggerated host response mechanisms driving the severe lung and other organ damage seen in coronavirus infection, this approach is a way of finding out whether these novel approaches are effective in treating the disease.
The treatments currently being tested in TACTIC-E are:
- EDP1815 – to modulate abnormal immune and inflammatory response to acute viral infection
- Ambrisentan in combination with Dapagliflozin – to treat respiratory, cardiovascular and renal complications from COVID-19
The platform design used by TACTIC-E provides flexibility to swap out and add in alternative treatments based on emerging data as the trial progresses.
For more information visit: CamCovidTrials
Published July 31, 2020
Latest from CCTU
Research sets global standard for Crohn’s treatment
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards…
Team praised for “game-changing” heart trial
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Improving outcomes for Crohn's patients
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
